FGF23 and chronic kidney disease: Hasegawa and Sugiura established a CKD model through injections of anti-glomerular basement membrane antiserum plus a high phosphate diet and found that the expression of Na/Pi transporters and 1α-hydroxylase exhibited more than a 50% reduction in the kidney after the 7 weeks, which could be reversed by FGF-23 antibody32,33.